Critical Review: Assessment of Interferon-β Immunogenicity in Multiple Sclerosis (Q37793157)

23 August 2017

title

Critical review: assessment of interferon-β immunogenicity in multiple sclerosis (English)

1 reference

23 August 2017

Critical Review: Assessment of Interferon-β Immunogenicity in Multiple Sclerosis (English)

1 reference

Crossref

https://api.crossref.org/works/10.1089/JIR.2010.0091

21 July 2024

0 references

Klaus Bendtzen

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20874253

21 July 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

http://www.liebertpub.com/doi/full-xml/10.1089/jir.2010.0091

1 reference

Crossref

https://api.crossref.org/works/10.1089/JIR.2010.0091

http://www.liebertpub.com/doi/pdf/10.1089/jir.2010.0091

21 July 2024

1 reference

Crossref

https://api.crossref.org/works/10.1089/JIR.2010.0091

Journal of Interferon and Cytokine Research

21 July 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

759-766

1 reference

Drug Insight: interferon treatment in multiple sclerosis.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Anti-IFN BAb and NAb antibodies: a minireview

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

High-avidity autoantibodies to cytokines

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Detection of autoantibodies to cytokines

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Autoantibodies to cytokines--friends or foes?

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Implications of neutralising antibodies on therapeutic efficacy.

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Comparative study of four different assays for the detection of binding antibodies against interferon-beta

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Quantitative liquid-phase chemiluminescence ELISA: detection of subtle epitope differences in HuIFN-beta

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Perspectives on the neutralization of interferons by antibody

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Immunogenicity assessment of therapeutic proteins and peptides

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

One-step assay for quantification of neutralizing antibodies to biopharmaceuticals

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Interferons, interferon-like cytokines, and their receptors

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

The promise and challenges of bioengineered recombinant clotting factors

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have?

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Predicting the response to infliximab from trough serum levels

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

Biologic therapies in rheumatology: lessons learned, future directions

21 July 2024

1 reference

https://api.crossref.org/works/10.1089/JIR.2010.0091

21 July 2024

Identifiers

1 reference

23 August 2017

1 reference